Novo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) Book value per share
Novo Nordisk A/S's book value per share at the end of fiscal 2025 was 6.6×, up 41.6% from 4.7× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 7.8×. Over the past ten years it has ranged from 1.3× (fiscal 2016) to 6.6× (fiscal 2025) — the current reading is the highest in ten years. Novo Nordisk A/S ranks 14th of 21 Drug Manufacturers General companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 6.6× | 41.55% |
| FY2024 | 4.7× | 35.34% |
| FY2023 | 3.5× | 32.28% |
| FY2022 | 2.6× | 6.49% |
| FY2021 | 2.5× | 17.89% |
| FY2020 | 2.1× | 14.32% |
| FY2019 | 1.8× | 11.00% |
| FY2018 | 1.6× | 7.07% |
| FY2017 | 1.5× | 15.07% |
| FY2016 | 1.3× | (2.18%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 7.8× | 8.41% |
| Mar 2026 | 7.2× | 8.28% |
| Dec 2025 | 6.6× | 10.49% |
| Sep 2025 | 6.0× | 4.02% |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| SNY Sanofi compare | 35.1× |
| AZN AstraZeneca PLC compare | 33.4× |
| AMGN Amgen Inc. compare | 26.5× |
| NVS Novartis AG compare | 19.8× |
| PFE Pfizer Inc. compare | 15.7× |
| GSK GSK PLC Sponsored ADR compare | 12.3× |
| BMY Bristol Myers Squibb Company compare | 11.5× |
| GILD Gilead Sciences, Inc. compare | 10.4× |
| NVO Novo Nordisk A/S | 7.8× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on NVO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement